Programs include XL184, a Phase III inhibitor of MET, VEGFR2 and RET, and XL281, a Phase I Inhibitor of RAF Kinase PRINCETON, N.J. & SOUTH SAN FRANCISCO, Calif., December 12, 2008 - (HSMN NewsFeed) - Bristol-Myers Squibb Company (NYSE: BMY) and Exelixis…
Biopharmaceuticals, Oncology
Bristol-Myers Squibb, Exelixis, XL184, XL281

If you are a sales professional or want to become one, or if you are looking for a new sales job, you will face one of the toughest interview processes of any job seeker.
0 Comments on “Bristol-Myers Squibb and Exelixis Enter Global Collaboration on 2 Novel Cancer Programs”
Leave a Comment